1
|
AbuBakr AH, Hassan HAFM, Abdalla A, Khowessah OM, Abdelbary GA. Therapeutic potential of cationic bilosomes in the treatment of carrageenan-induced rat arthritis via fluticasone propionate gel. Int J Pharm 2023; 635:122776. [PMID: 36841370 DOI: 10.1016/j.ijpharm.2023.122776] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 02/10/2023] [Accepted: 02/20/2023] [Indexed: 02/25/2023]
Abstract
Arthritis is a debilitating disease that affects the patient's mobility and quality of life. This study focused on the development and optimization of a cationic nanosized bilosomal formula for the efficient transdermal treatment of arthritis. An optimum Fluticasone Propionate-loaded bilosomes (OFP) was developed using the Draper-Lin small composite design based on the optimization of 4 factors and evaluation of entrapment efficiency (Y1), vesicle size (Y2), skin flux (Y3), and skin accumulation (Y4). The OFP was characterized against the drug suspension, loaded into a Carbopol gel, and a histopathological assessment was conducted on a carrageenan-induced rat joint arthritis in comparison with cultivate® cream and traditional gel. Interluekin-1β and TNF-α levels were also measured. The optimal formula was formulated using 2.99% phospholipon90G, 0.04% sodium deoxycholate, and 0.29% stearylamine, and showed 84.72%, 268.13 nm, 5.89 µg/cm2/h, and 16.21 µg/cm2 /24 h for Y1, Y2, Y3, and Y4, respectively. The thermal analysis of OFP demonstrated a single broad endothermic peak for bilosomes with no detectable peak for the amorphous drug. TEM images revealed the spherical structures of the nanosized OFP, while CLSM demonstrated enhanced permeation efficiency over the drug suspension. The in-vivo study further proved the promising efficacy of the optimum OFP, where a complete recovery of the normal histological structure of a rat joint and normal levels of the inflammatory markers were observed within 20 days following once daily application of the optimum bilosomal gel. Therefore, OFP represents a competent nanocarrier for efficient transdermal management of joint arthritis.
Collapse
Affiliation(s)
- Abdel-Hameed AbuBakr
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Egyptian Russian University, Po.Box 11829, Badr City, Cairo, Egypt.
| | - Hatem A F M Hassan
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt; School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, New Administrative Capital, Cairo, Egypt
| | - Ahmed Abdalla
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Egyptian Russian University, Po.Box 11829, Badr City, Cairo, Egypt
| | - Omneya M Khowessah
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt
| | - Ghada A Abdelbary
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt
| |
Collapse
|
2
|
Proshutinskaya DV, Makoveckaya OS. Clinical features of mastocytosis at pediatric patients. VESTNIK DERMATOLOGII I VENEROLOGII 2017. [DOI: 10.25208/0042-4609-2017-93-1-12-20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Mastocytosis is relevant to heterogeneous disease group characterized with redundant accumulation and proliferation of mast cells in tissues. The skin form of mastocytosis is mainly occurs in children. The article contains the current data on etiology, pathogenesis, classification, clinical forms, diagnosis, prophylactics and mastocytosis treatment at children.
Collapse
|
3
|
Tamay Z, Özçeker D. Current approach to cutaneous mastocytosis in childhood. Turk Arch Pediatr 2016; 51:123-127. [PMID: 27738395 DOI: 10.5152/turkpediatriars.2016.2418] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 02/20/2016] [Indexed: 11/22/2022]
Abstract
Mastocytosis is a heterogeneous disorder characterized by clonal proliferation and accumulation of mast cells in one of more organs which may lead to different clinical pictures. Pathological increase and activation of mast cells in various tissues can cause different clinical pictures. Cutaneous mastocytosis limited to the skin is the most typical clinical picture observed in children and systemic mastocytosis is very rare in the pediatric age group. The diagnosis of cutaneous mastocytosis is based on clinical findings, but is often delayed due to lack of clinical awareness of the disease and lack of its consideration in the differential diagnosis. This article focuses on the current diagnosis, management and treatment of cutaneous mastocytosis in children in order to increase awareness about this issue.
Collapse
Affiliation(s)
- Zeynep Tamay
- Division of Pediatric Immunology and Allergy, Department of Pediatric, İstanbul University İstanbul School of Medicine, İstanbul, Turkey
| | - Deniz Özçeker
- Division of Pediatric Immunology and Allergy, Department of Pediatric, İstanbul University İstanbul School of Medicine, İstanbul, Turkey
| |
Collapse
|
4
|
Ferrante G, Scavone V, Muscia MC, Adrignola E, Corsello G, Passalacqua G, La Grutta S. The care pathway for children with urticaria, angioedema, mastocytosis. World Allergy Organ J 2015; 8:5. [PMID: 25674297 PMCID: PMC4313464 DOI: 10.1186/s40413-014-0052-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 12/11/2014] [Indexed: 12/31/2022] Open
Abstract
Cutaneous involvement characterized by urticarial lesions with or without angioedema and itch is commonly observed in routine medical practice. The clinical approach may still remain complex in real life, because several diseases may display similar cutaneous manifestations. Urticaria is a common disease, characterized by the sudden appearance of wheals, with/without angioedema. The term Chronic Urticaria (CU) encompasses a group of conditions with different underlying causes and different mechanisms, but sharing the clinical picture of recurring wheals and/or angioedema for at least 6 weeks. Hereditary Angioedema (HAE) is a rare disorder characterized by recurrent episodes of non-pruritic, non-pitting, subcutaneous or submucosal edema affecting the extremities, face, throat, trunk, genitalia, or bowel, that are referred as “attacks”. HAE is an autosomal dominant disease caused by a deficiency of functional C1 inhibitor, due to a mutation in C1-INH gene (serping 1 gene) characterized by the clonal proliferation of mast cells, leading to their accumulation, and possibly mediator release, in one or more organs. In childhood there are two main forms of mastocytosis, the Systemic and the Cutaneous. The clinical features of skin lesions in urticaria, angioedema and mastocytosis may differ depending on the aetiologic factors, and the underlying pathophysiological mechanisms. The diagnostic process, as stepwise approach in routine clinical practice, is here reviewed for CU, HAE and mastocytosis, resulting in an integrated method for improved management of these cutaneous diseases. Taking into account that usually these conditions have also a relevant impact on the quality of life of children, affecting social activities and behavior, the availability of care pathways could be helpful in disentangle the diagnostic issue achieving the most cost-effective ratio.
Collapse
Affiliation(s)
- Giuliana Ferrante
- Department of Science for Health Promotion and Mother and Child Care, Università di Palermo, Via del Vespro, 133, 90127 Palermo, Italy
| | - Valeria Scavone
- Department of Science for Health Promotion and Mother and Child Care, Università di Palermo, Via del Vespro, 133, 90127 Palermo, Italy
| | - Maria Concetta Muscia
- Department of Science for Health Promotion and Mother and Child Care, Università di Palermo, Via del Vespro, 133, 90127 Palermo, Italy
| | - Emilia Adrignola
- Department of Science for Health Promotion and Mother and Child Care, Università di Palermo, Via del Vespro, 133, 90127 Palermo, Italy
| | - Giovanni Corsello
- Department of Science for Health Promotion and Mother and Child Care, Università di Palermo, Via del Vespro, 133, 90127 Palermo, Italy
| | - Giovanni Passalacqua
- Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS San Martino, University of Genoa, Genoa, Italy
| | - Stefania La Grutta
- Institute of Biomedicine and Molecular Immunology IBIM, National Research Council, Palermo, Italy
| |
Collapse
|
5
|
Barathi M, Rai R, Srinivas CR. The efficacy of clobetasol propionate with varying dilutions of emollient determined by histamine wheal suppression test. Indian J Dermatol 2011; 56:527-8. [PMID: 22121270 PMCID: PMC3221215 DOI: 10.4103/0019-5154.87146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Background: The ability of steroids to reduce the histamine wheal was used to assess the efficacy of topical clobetasol propionate with varying dilutions of emollients. Aim: To determine the wheal-suppressing ability of topical clobetasol with varying dilutions of emollient. Materials and Methods: It was a double-blinded randomized study. Twenty-five volunteers were included in the study. Five syringes of 5 ml were taken and the syringes were loaded with either clobetasol propionate 0.05%, emollient, or clobetasol propionate with emollient in dilutions of 1:1, 1:2, and 1:3. The syringes were coded 1 to 5. Five squares of 3 × 3 cm were marked on the flexor aspect of the forearm of the volunteers. After randomization, half fingertip unit of the cream was applied within each square uniformly. Three hours later histamine prick test was performed by the standard method. The wheal was measured after 15 min and the results were recorded. After decoding, results were statistically analyzed by analysis of variance. Result: The decrease in wheal suppression of steroid with emollient (1:1) was same as topical steroid and the wheal suppression decreased with increasing dilutions of steroid. Conclusion: We conclude that steroids and emollients can be mixed in equal proportion (1:1) and the effect is same as steroid alone and increasing dilution of steroids with emollients was not effective in suppressing the wheal.
Collapse
Affiliation(s)
- M Barathi
- Department of Dermatology, PSG Institute of Medical Science and Research, Coimbatore, Tamil Nadu, India
| | | | | |
Collapse
|
6
|
Abstract
Mastocytosis is a disorder characterized by increased numbers of mast cells in tissues. Recent clinical observations highlight the association of mastocytosis with an increased risk of anaphylaxis and underline the diversity of this disease. At the molecular level, recent studies have attempted to unravel specific gene expression profiles for activating c-kit mutations in the etiology of mastocytosis. The diagnosis may be facilitated by surrogate markers and detection of aberrant immunophenotypic surface markers. New therapeutic strategies are in development based on intracellular signal pathways, or on application of topical treatments, as are novel forms of cytoreductive therapy, including tyrosine kinase inhibitors.
Collapse
|
7
|
Maluf LC, Barros JAD, Machado Filho CDADS. Mastocytosis. An Bras Dermatol 2010; 84:213-25. [PMID: 19668934 DOI: 10.1590/s0365-05962009000300002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2009] [Accepted: 02/17/2009] [Indexed: 11/21/2022] Open
Abstract
Mastocytosis is characterized by pathologic accumulation and activation of mast cells in tissues and organs. Although the classification for mastocytosis and diagnostic criteria are well accepted, there remains a need to define standards for the application of diagnostic tests, clinical evaluations, and responses to treatment. The objective of this article was to make an extensive literature review, providing comprehensive knowledge about the etiopathological and pathophysiological mechanisms, with a special emphasis on diagnosis, classification and treatment of mastocytosis, promoting continued medical education.
Collapse
Affiliation(s)
- Luciana Cirillo Maluf
- Mestre em Ciências da Saúde pela Faculdade de Medicina do ABC, Preceptor da disciplina de Dermatologia da Faculdade de Medicina do ABC, Santo André (SP), Brazil.
| | | | | |
Collapse
|
8
|
Heide R, Beishuizen A, De Groot H, Den Hollander JC, Van Doormaal JJ, De Monchy JGR, Pasmans SGMA, Van Gysel D, Oranje AP. Mastocytosis in children: a protocol for management. Pediatr Dermatol 2008; 25:493-500. [PMID: 18789103 DOI: 10.1111/j.1525-1470.2008.00738.x] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Mastocytosis is characterized by an increased number of mast cells with an abnormal growth and accumulation in one or more organs. In most children mastocytosis is limited to the skin (cutaneous mastocytosis) and often transient as compared with that in adults in whom mastocytosis is usually progressive and systemic. Generally, we recognize three more common forms of cutaneous mastocytosis: maculopapulous mastocytosis (formerly urticaria pigmentosa), mastocytoma of skin, and diffuse cutaneous mastocytosis. Childhood mastocytosis can further be divided into cutaneous mastocytosis (nonpersisting and persisting) and systemic mastocytosis (extremely rare). An approach to management using a set protocol is described in table form. In most cases of mastocytosis, only yearly checkups are necessary and no treatment is required; preventive recommendations are warranted in those individuals with systemic disease and constitutional symptoms. Symptomatic therapy is advised in only a minority of cases. This article is meant as a guideline for physicians involved in the care of children with mastocytosis and their parents.
Collapse
Affiliation(s)
- Rogier Heide
- Department of Dermatology, Medisch Centrum Alkmaar, Alkmaar, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Oranje AP, Heide R, de Waard-van der Spek FB, Gysel DV, Tank B. Recent advances in mast cell-related skin diseases: particular focus on mastocytosis and urticaria. EXPERT REVIEW OF DERMATOLOGY 2008; 3:65-72. [DOI: 10.1586/17469872.3.1.65] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/10/2024]
|